POINT Biopharma Global is a radiopharmaceutical company focusing on the clinical development and commercialization of radioligands for cancer treatment. Co.'s product candidates include: PNT2002, which is a prostate-specific membrane antigen (PSMA) targeted radioligand for the treatment of metastatic castration-resistant prostate cancer; PNT2004, which is a fibroblast activation protein-a targeting program being developed for use in several tumor types; PNT2003, which is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors; and PNT2001, which is a PSMA targeting ligand family that utilizes linker technology that promotes increased tumor accumulation. The PNT stock yearly return is shown above.
The yearly return on the PNT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PNT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|